Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Adds Dual-Acting Insomnia Compound With Acquisition Of Hypnion

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal will add the Phase II compound HY10275 to Lilly’s existing insomnia candidate pruvanserin.
Advertisement

Related Content

Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
Lilly Puts On A Happy Face, But Will Investors Buy In?
Lilly Puts On A Happy Face, But Will Investors Buy In?
Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS065843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel